摘要

Authors' objectives: The objective of this health technology assessment is to address questions regarding: 1) safety, effectiveness and health services utilisation associated with the use of Elecsys immunoassay sFlt-1/PlGF ratio, Triage PlGF-test, DELFIA Xpress PlGF 1-2-3 test, BRAHMS sFlt-1 Kryptor/BRAHMS PlGF-pluss Kryptor PE ratio or other blood-based tests for predicting suspected preeclampsia in 2nd and 3rd trimester; 2) predictive accuracy of these tests; 3) cost-effectiveness and budgetary consequences of implementation; and evaluate the intervention against the priority setting criteria applicable in Norway (benefit, resource use and severity).